DOI:
10.1055/s-00000071
Seminars in Neurology
LinksClose Window
References
Coles AJ, Cohen JA, Arnold DL. , et al.
On behalf of the CARE-MS I Investigators. Alemtuzumab provides durable improvements in clinical outcomes in treatment-naive patients with active relapsing remitting multiple sclerosis over 6 years in the absence of continuous treatment (CARE-MS I).
Mult Scler 2016;
22 (S3): 75
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.